Rhenman & Partners Asset Management AB — 13F holdings

Rhenman & Partners Asset Management AB reported 99 holdings worth $1.06B in its 13F filing for Q2 2026, filed August 13, 2026. That's up 30.7% from $810M in Q1 2026, when it reported 86 holdings. Its 10 largest positions make up 25.1% of the portfolio.

Rhenman & Partners Asset Management AB's largest positions in Q2 2026

  1. UNH UNITEDHEALTH GROUP INC — $38.9M (3.7%) · added 106%
  2. CVS CVS HEALTH CORP — $28.9M (2.7%) · cut 17%
  3. AZN ASTRAZENECA PLC — $28.5M (2.7%) · new position
  4. MRK MERCK & CO INC — $27.4M (2.6%) · new position
  5. LLY ELI LILLY & CO — $26.8M (2.5%) · cut 34%
  6. ABBV ABBVIE INC — $24.4M (2.3%) · added 35%
  7. ALHC ALIGNMENT HEALTHCARE INC — $23.7M (2.2%) · cut 5%
  8. EW EDWARDS LIFESCIENCES CORP — $23.5M (2.2%) · added 60%
  9. GILD GILEAD SCIENCES INC — $22.5M (2.1%) · added 6%
  10. JAZZ JAZZ PHARMACEUTICALS PLC — $21.1M (2.0%) · added 15%
  11. BIIB BIOGEN INC — $20.5M (1.9%) · cut 13%
  12. SYK STRYKER CORPORATION — $20.5M (1.9%) · added 36%
  13. BSX BOSTON SCIENTIFIC CORP — $19.2M (1.8%) · cut 28%
  14. JNJ JOHNSON & JOHNSON — $18.4M (1.7%) · new position
  15. GH GUARDANT HEALTH INC — $17.3M (1.6%) · cut 21%
  16. REGN REGENERON PHARMACEUTICALS — $17.1M (1.6%) · cut 43%
  17. GKOS GLAUKOS CORP — $16.6M (1.6%) · added 42%
  18. BMRN BIOMARIN PHARMACEUTICAL INC — $16.6M (1.6%) · added 40%
  19. NRIX NURIX THERAPEUTICS INC — $16.6M (1.6%) · added 118%
  20. NTRA NATERA INC — $16.6M (1.6%) · added 18%

What Rhenman & Partners Asset Management AB bought in Q2 2026

21 new positions and 40 positions added to.

  1. AZN ASTRAZENECA PLC — new position, about $28.5M
  2. MRK MERCK & CO INC — new position, about $27.4M
  3. UNH UNITEDHEALTH GROUP INC — added, about $20.0M
  4. JNJ JOHNSON & JOHNSON — new position, about $18.4M
  5. CNC CENTENE CORP DEL — new position, about $15.7M
  6. DHR DANAHER CORPORATION — added, about $11.8M
  7. DXCM DEXCOM INC — new position, about $10.8M
  8. SYRE SPYRE THERAPEUTICS INC — new position, about $10.6M
  9. ALGN ALIGN TECHNOLOGY INC — added, about $9.36M
  10. NRIX NURIX THERAPEUTICS INC — added, about $8.99M

What Rhenman & Partners Asset Management AB sold in Q2 2026

8 positions sold out and 34 reduced.

  1. ADPT ADAPTIVE BIOTECHNOLOGIES COR — sold out, about $15.4M
  2. LLY ELI LILLY & CO — cut 34%, about $13.7M
  3. REGN REGENERON PHARMACEUTICALS — cut 43%, about $12.9M
  4. VEEV VEEVA SYS INC — cut 80%, about $12.1M
  5. IQV IQVIA HLDGS INC — sold out, about $10.2M
  6. NUVL NUVALENT INC — sold out, about $10.0M
  7. APGE APOGEE THERAPEUTICS INC — sold out, about $9.95M
  8. MDGL MADRIGAL PHARMACEUTICALS INC — cut 67%, about $8.59M
  9. OSCR OSCAR HEALTH INC — cut 41%, about $7.64M
  10. BSX BOSTON SCIENTIFIC CORP — cut 28%, about $7.45M

Rhenman & Partners Asset Management AB portfolio value by quarter

What does Rhenman & Partners Asset Management AB own?

Its largest positions in Q2 2026 were UNH, CVS, AZN, MRK, LLY, out of 99 holdings worth $1.06B.

What did Rhenman & Partners Asset Management AB buy last quarter?

In Q2 2026 it opened 21 new positions and added to 40; the largest buys were AZN, MRK, UNH.

What did Rhenman & Partners Asset Management AB sell last quarter?

In Q2 2026 it sold out of 8 positions and reduced 34, including ADPT, IQV, NUVL.